ftp105 Antibody

What is TAFII p105 and what cellular functions does it regulate?

TAFII p105, also known as TAF4B, is a cell-type specific transcriptional co-activator that functions as a component of the TFIID complex. It is primarily expressed in B cells and ovarian granulosa cells, where it plays crucial roles in transcriptional regulation. TAFII p105 interacts with OCBA/POU2AF1 to activate B cell-specific octamer-dependent transcription. Additionally, this protein plays an important role in co-activating the transcription factor NFκB and is essential for activation of anti-apoptotic genes such as TNFAIP3 .

In contrast to the related TAFII p135 (TAF4/TAF4A) which is more ubiquitously expressed, TAFII p105 has tissue-specific functions, making it an important target for studying tissue-specific transcriptional regulation. The selective expression pattern in B cells and ovarian cells makes it particularly valuable for research in immunology and reproductive biology.

What are the key characteristics of commercial TAFII p105 antibodies?

Commercial antibodies against TAFII p105 typically detect endogenous protein at molecular weights of both 135 kDa and 105 kDa. High-quality preparations demonstrate >95% purity by SDS-PAGE analysis . These antibodies recognize specific epitopes on the TAFII protein complex that may include both TAF4B (p105) and TAF4/TAF4A (p135).

When selecting an antibody for research purposes, researchers should verify whether the antibody detects just the TAF4B (p105) isoform specifically or both TAF4 family members. This distinction is important for experimental design, particularly when studying tissue-specific transcriptional regulation where the differential expression of these isoforms may be critical.

How is TAFII p105 antibody different from other transcription factor antibodies?

TAFII p105 antibody differs from other transcription factor antibodies in its specificity for components of the TFIID complex, particularly recognizing the cell-type specific TAF4B variant. Unlike antibodies against more general transcription factors like RNA polymerase II or TBP (TATA-binding protein), TAFII p105 antibody targets a protein with more restricted expression patterns and specialized functions .

What are the optimal conditions for using TAFII p105 antibody in Western blotting?

When performing Western blotting with TAFII p105 antibody, researchers should optimize several parameters to ensure specific detection:

• Sample preparation: Nuclear extracts typically yield better results than whole cell lysates due to the nuclear localization of TAFII p105.

• Gel percentage: Use 6-8% SDS-PAGE gels to adequately resolve the high molecular weight bands (105 kDa and 135 kDa).

• Transfer conditions: Extended transfer times (overnight at low voltage or 2 hours at high voltage) improve transfer efficiency of high molecular weight proteins.

• Blocking: 5% non-fat dry milk in TBST is generally effective, though BSA may provide lower background in some cases.

• Antibody dilution: Typically 1:500 to 1:2000 depending on the specific antibody preparation, with overnight incubation at 4°C.

Since TAFII p105 antibody detects proteins at both 135 kDa and 105 kDa molecular weights , proper molecular weight markers and positive controls are essential to distinguish between the two bands. When analyzing B cells or ovarian tissue samples, the 105 kDa band (TAF4B) may be more prominent compared to other cell types where the 135 kDa band (TAF4/TAF4A) predominates.

How can TAFII p105 antibody be effectively used in chromatin immunoprecipitation (ChIP) experiments?

For successful chromatin immunoprecipitation with TAFII p105 antibody:

• Crosslinking: Standard formaldehyde crosslinking (1% for 10 minutes) works well for most TFIID components.

• Sonication: Optimize sonication conditions to generate DNA fragments of 200-500 bp.

• Antibody amount: 2-5 μg of antibody per ChIP reaction is typically sufficient.

• Beads: Protein A/G magnetic beads often provide cleaner results than agarose beads.

• Controls: Include IgG control and positive control antibody (e.g., anti-RNA Pol II) in parallel experiments.

Sequential ChIP (ChIP-reChIP) can be particularly valuable when studying TAFII p105, as it allows researchers to identify genomic regions where TAF4B co-localizes with other transcription factors such as NFκB or cell-specific factors like OCBA/POU2AF1 in B cells. This approach provides insights into the cooperative assembly of transcriptional complexes at specific genomic loci.

What approaches can be used to distinguish between TAFII p105 (TAF4B) and TAFII p135 (TAF4) in experimental systems?

Distinguishing between these related proteins requires strategic experimental approaches:

• Selective knockdown: siRNA or shRNA targeting unique regions of TAF4B mRNA can selectively deplete p105 without affecting p135 expression.

• Cell-type specificity: Using B cells or ovarian granulosa cells, which highly express TAF4B, versus other cell types with low TAF4B expression.

• Specific antibody epitopes: Some antibody preparations may recognize unique epitopes in either protein.

• Molecular weight discrimination: Careful analysis of Western blots with high-resolution gels can separate the 105 kDa and 135 kDa bands.

• Mass spectrometry: For definitive identification, immunoprecipitated proteins can be analyzed by mass spectrometry.

The TAFII p105 (TAF4B) protein has distinct functional properties compared to TAFII p135 (TAF4/TAF4A), particularly in its ability to interact with OCBA/POU2AF1 and activate B cell-specific gene expression . Therefore, functional assays measuring these specific activities can also help distinguish between the two proteins.

How can TAFII p105 antibody be used to study cell-type specific transcriptional regulation?

TAFII p105 (TAF4B) shows distinct expression patterns in B cells and ovarian granulosa cells, making it an excellent model for studying tissue-specific transcriptional mechanisms:

• Comparative ChIP-seq: Apply ChIP-seq with TAFII p105 antibody across different cell types to identify cell-type specific binding sites.

• Integrated multi-omics: Combine ChIP-seq data with RNA-seq and ATAC-seq to correlate TAF4B binding with gene expression and chromatin accessibility.

• Co-immunoprecipitation (Co-IP): Use TAFII p105 antibody for Co-IP followed by mass spectrometry to identify cell-type specific protein interaction networks.

• Conditional knockout models: Study the effects of tissue-specific TAF4B deletion on transcriptional programs.

The ability of TAFII p105 to interact with OCBA/POU2AF1 in B cells represents a paradigm for how general transcription factors can acquire tissue specificity through interactions with lineage-specific regulators . Studying these mechanisms can provide broader insights into transcriptional specialization during development and differentiation.

What are the methodological approaches for investigating TAFII p105's role in NFκB-dependent transcriptional activation?

TAFII p105 plays a critical role in co-activating NFκB and regulating anti-apoptotic gene expression . To investigate this function:

• Sequential ChIP: Perform ChIP-reChIP with TAFII p105 antibody followed by NFκB antibody to identify co-occupied genomic regions.

• Reporter assays: Use NFκB-responsive luciferase reporters in systems with normal or depleted TAF4B levels.

• Proximity ligation assay (PLA): Visualize in situ interaction between TAF4B and NFκB components.

• Inducible systems: Study TAF4B recruitment to NFκB-dependent promoters following TNFα or other NFκB-activating stimuli.

• Domain mapping: Use truncated constructs to identify which domains of TAF4B are essential for NFκB co-activation.

This research is particularly relevant for understanding B cell survival mechanisms and inflammatory responses, as NFκB signaling is central to these processes. TAF4B's involvement suggests that the general transcription machinery is not merely a passive recipient of regulatory signals but actively contributes to pathway-specific responses.

How can protein-protein interaction studies be optimized using TAFII p105 antibody?

For detailed characterization of TAF4B protein interactions:

• Nuclear extract preparation: Optimize salt concentration (typically 300-420 mM) to maintain nuclear protein complexes.

• Co-IP buffer composition: Use buffers containing 0.1-0.5% NP-40 with careful titration of salt concentration to preserve specific interactions.

• Antibody orientation: Compare results with TAF4B antibody as the immunoprecipitating antibody versus as a detection antibody after IP with antibodies against putative interacting partners.

• Crosslinking approaches: Consider reversible crosslinkers like DSP to stabilize transient interactions.

• Size exclusion chromatography: Combine with Western blotting using TAFII p105 antibody to identify which complexes contain TAF4B.

The TAFH domain of TAFII p105 is thought to mediate interactions with glutamine-rich domains in transcription factors such as CREB . Systematic mapping of these interaction networks can reveal how TAF4B contributes to both general and specialized transcriptional regulation.

What are common issues with TAFII p105 antibody specificity and how can they be addressed?

Researchers may encounter several specificity issues when working with TAFII p105 antibody:

• Cross-reactivity: The antibody detecting both p105 (TAF4B) and p135 (TAF4) can complicate interpretation . This can be addressed by:

  • Using lysates from cells known to express only one isoform as controls

  • Performing knockdown experiments to confirm band identity

  • Using multiple antibodies targeting different epitopes

• Background bands: Non-specific bands may appear, particularly in whole cell lysates. To minimize this:

  • Use nuclear extracts when possible

  • Increase washing stringency in Western blotting

  • Optimize blocking conditions (try different blocking agents)

• Batch variability: Different lots of the same antibody may show varying specificity profiles. Researchers should:

  • Test each new lot against a reference sample

  • Maintain detailed records of antibody performance

  • Consider preparing larger quantities of a well-characterized lot for long-term studies

How can researchers validate TAFII p105 antibody performance in different experimental systems?

Comprehensive validation approaches include:

• Genetic controls:

  • Use TAF4B knockout or knockdown cells/tissues

  • Compare tissues with known differential expression (B cells vs. fibroblasts)

  • Use overexpression systems with tagged constructs

• Epitope mapping:

  • Determine which region of TAF4B the antibody recognizes

  • Test antibody against recombinant fragments of the protein

  • Consider epitope competition assays

• Multi-method validation:

  • Compare results across techniques (Western blot, IP, ChIP, immunofluorescence)

  • Use orthogonal approaches (mass spectrometry identification of immunoprecipitated proteins)

  • Correlate protein detection with mRNA expression data

• Reproducibility testing:

  • Test across different cell types and experimental conditions

  • Compare with other antibodies against the same target

  • Validate critical findings with alternative methodologies

Proper validation is particularly important when studying complexes like TFIID, where multiple related subunits with similar molecular weights can complicate interpretation.

What quality control metrics should be established for TAFII p105 antibody in ChIP-seq experiments?

For robust ChIP-seq experiments using TAFII p105 antibody, establish these quality control metrics:

• Pre-sequencing QC:

  • Perform ChIP-qPCR on known target loci before sequencing

  • Assess enrichment relative to input and IgG control (>8-fold enrichment recommended)

  • Check DNA fragment size distribution (optimal 200-500 bp)

• Post-sequencing QC:

  • Calculate library complexity metrics (NRF, PBC1, PBC2)

  • Determine fraction of reads in peaks (FRiP) score (>1% recommended)

  • Assess peak reproducibility between biological replicates

• Control comparisons:

  • Compare against appropriate input control

  • Include IgG control libraries

  • Consider using TAF4B-depleted cells as negative controls

• Biological validation:

  • Confirm enrichment at expected target genes (e.g., NFκB targets in B cells)

  • Perform motif analysis to confirm enrichment of expected transcription factor binding sites

  • Correlate binding with gene expression data

Establishing these metrics allows for standardized quality assessment across experiments and facilitates comparison with published datasets.

How does TAFII p105 contribute to B cell-specific transcriptional programs?

TAFII p105 (TAF4B) plays a specialized role in B cell transcription through several mechanisms:

• Interaction with B cell-specific factors: TAF4B interacts with OCBA/POU2AF1 to activate B cell-specific octamer-dependent transcription . This represents a paradigm for how general transcription components can acquire tissue specificity.

• NFκB pathway integration: In B cells, TAF4B is essential for activation of anti-apoptotic genes such as TNFAIP3 through its co-activator function with NFκB . This is critical for B cell survival during immune responses.

• Developmental regulation: TAF4B contributes to stage-specific gene expression programs during B cell development and differentiation, particularly in germinal center reactions.

• Chromatin regulatory functions: Beyond its role in TFIID, TAF4B may influence chromatin accessibility at B cell-specific enhancers and promoters.

Research methodologies to study these functions include ChIP-seq in primary B cells at different developmental stages, genetic models with B cell-specific TAF4B deletion, and integrative genomics approaches comparing TAF4B binding with lineage-specific transcription factors.

What experimental approaches can reveal the distinct functions of TAFII p105 in comparison to TAFII p135?

Although TAFII p105 (TAF4B) and TAFII p135 (TAF4/TAF4A) share significant sequence homology, they have distinct biological functions . To investigate these differences:

• Selective depletion experiments:

  • Use siRNA targeting unique regions to selectively deplete one isoform

  • Analyze transcriptome changes using RNA-seq

  • Compare chromatin binding patterns by ChIP-seq

• Domain swapping experiments:

  • Create chimeric constructs swapping domains between TAF4B and TAF4

  • Assess which domains confer functional specificity

  • Test in rescue experiments after endogenous protein depletion

• Interactome analysis:

  • Compare protein interaction networks using BioID or proximity labeling

  • Identify isoform-specific interacting partners

  • Map interaction domains using truncation mutants

• In vivo functional comparisons:

  • Use knockout mouse models with tissue-specific rescue by either TAF4B or TAF4

  • Assess which functions can be complemented by the other isoform

  • Analyze tissue-specific phenotypes

These comparative approaches can reveal how structural differences between these related proteins translate into distinct functional properties in transcriptional regulation.

How can new methodologies enhance the utility of TAFII p105 antibody in studying dynamic transcriptional processes?

Emerging technologies are expanding the applications of TAFII p105 antibody in studying dynamic transcriptional regulation:

• CUT&RUN and CUT&Tag:

  • Offer higher signal-to-noise ratio than traditional ChIP

  • Require fewer cells (as few as 1,000)

  • Allow study of TAF4B binding in rare cell populations

• Live-cell imaging approaches:

  • Use fluorescently tagged nanobodies derived from TAFII p105 antibodies

  • Track dynamic assembly/disassembly of transcription complexes

  • Measure residence times at specific genomic loci

• Single-cell technologies:

  • Adapt TAFII p105 antibody for CyTOF or scCUT&Tag

  • Correlate TAF4B binding with single-cell transcriptomes

  • Identify cell-state-specific regulatory mechanisms

• Spatial genomics integration:

  • Combine TAFII p105 antibody-based chromatin mapping with spatial transcriptomics

  • Study nuclear organization of TAF4B-dependent transcription

  • Map three-dimensional interactions using antibody-based approaches like HiChIP

These methodological advances will allow researchers to study TAF4B function with unprecedented resolution across temporal, spatial, and cell-state dimensions.

What are the implications of recent findings about TAFII p105 for understanding disease mechanisms?

Recent research has implicated TAFII p105 (TAF4B) in several disease contexts:

• B cell malignancies:

  • Aberrant TAF4B activity may contribute to B cell lymphoma development

  • TAF4B-dependent anti-apoptotic mechanisms may confer resistance to therapy

  • Research using TAFII p105 antibody in patient samples may identify new diagnostic or prognostic markers

• Inflammatory disorders:

  • TAF4B's role in NFκB co-activation links it to inflammatory pathways

  • Studying TAF4B binding at inflammatory gene loci can reveal mechanisms of chronic inflammation

  • TAF4B may represent a novel therapeutic target for modulating inflammatory responses

• Reproductive disorders:

  • Given TAF4B's expression in ovarian granulosa cells , it may play roles in ovarian pathologies

  • TAF4B dysregulation could contribute to infertility or ovarian cancer

  • TAFII p105 antibody can be used to study TAF4B in ovarian tissue samples

Methodological approaches to study these disease implications include tissue microarrays with TAFII p105 antibody staining, integrated genomic analyses of disease models, and TAF4B interactome characterization in normal versus disease states.

How can computational approaches enhance the analysis of TAFII p105 antibody-generated data?

Advanced computational methods can extract deeper insights from experiments using TAFII p105 antibody:

• Integrative analysis frameworks:

  • Combine ChIP-seq, RNA-seq, ATAC-seq, and Hi-C data to build comprehensive regulatory models

  • Use machine learning to identify patterns in TAF4B binding and function

  • Develop network models incorporating TAF4B interactions

• Motif analysis and transcription factor cooperativity:

  • Identify transcription factor motifs enriched near TAF4B binding sites

  • Model cooperative binding relationships

  • Predict functional outcomes of specific binding configurations

• Comparative genomics approaches:

  • Analyze TAF4B binding site conservation across species

  • Identify evolutionarily conserved regulatory mechanisms

  • Study lineage-specific adaptations in TAF4B function

• Structural modeling of interactions:

  • Use protein structure prediction to model TAF4B interactions with other factors

  • Design experiments to test structural predictions

  • Facilitate development of more specific antibodies or inhibitors

These computational approaches transform antibody-generated data from descriptive observations to predictive models of transcriptional regulation.

What are the most promising future directions for TAFII p105 antibody applications in transcriptional research?

The future of TAFII p105 antibody-based research holds several promising directions:

• Single-molecule studies: Adapting TAFII p105 antibodies for single-molecule tracking to study the dynamics of transcription complex assembly in real-time.

• Structural biology integration: Combining antibody-based proximity labeling with cryo-EM to resolve the structure of TAF4B-containing complexes.

• Cell-type atlas development: Using TAFII p105 antibody in large-scale efforts to map transcription factor binding across all human cell types.

• Therapeutic targeting strategies: Developing approaches to modulate TAF4B function in disease contexts, potentially through targeted protein degradation.

• Multi-antibody combinatorial approaches: Simultaneously probing multiple components of transcriptional complexes to understand their stoichiometry and assembly rules.